Species |
Human |
Protein Construction |
IFN-α 2a (Cys24-Glu188) Accession # P01563 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
ED50 < 0.1 ng/ml, measured by a cytotoxicity assay using TF-1 Cells, corresponding to a specific activity of > 1.0 × 107 units/mg. |
Expression System |
E. coli |
Apparent Molecular Weight |
~19.2 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Biological Activity
IFN-alpha 2a, Human (Cat. No. Z03003) induced cytotoxicity of R&D TF-1 cells. The ED50 for this effect is less than 0.1ng/mL.
2 μg of IFN-α 2a, Human (Cat. No. Z03003) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.
Target Background |
Interferon-Alpha 2a (IFN-Alpha 2a), Human produced by leukocytes is a member of Interferon family. IFN-alpha is mainly involved in innate immune response against a broad range of viral infections. IFN-alpha 2 has three acid stable forms (a,b,c) signaling through IFNAR2. IFN-alpha 2a shares 99.4% , 98.8% aa sequence identity with IFN-alpha 2b and 2c respectively. IFN-alpha contains four highly conserved cysteine residues which form two disulfide bonds, one of which is necessary for biological activity. |
Synonyms |
Leukocyte interferon; B cell interferon; Type I interferon; IFNA2; IFN-a 2a |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.